Novo Nordisk Ozempic Lawsuit: Your 2026 Claims Guide

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

As of September 3, 2026, MDL 3094 has grown to roughly 3,928 pending gastrointestinal injury cases, with the Hon. Karen Spencer Marston now presiding in the Eastern District of Pennsylvania. In December 2025, a separate MDL (No. 3163) was created for vision-loss (NAION) claims tied to GLP-1 drugs, which has grown to roughly 146 pending cases — a track not covered above. Summary judgment briefing wrapped in July 2026 and Daubert motions are now fully briefed, but no bellwether trial has occurred and no global settlement has been reached in either MDL. Status conferences continue roughly monthly through the end of 2026.

Last updated: September 2026

Explore this too: Reed-Nelson Lawsuit 2026: Settlement and Payout Guide

The Novo Nordisk Ozempic lawsuit is one of the largest pharmaceutical cases heading into 2026, with thousands of plaintiffs claiming the company hid dangerous side effects. If you took Ozempic and suffered gastroparesis, stomach paralysis, or bowel obstruction, you may be entitled to significant compensation.

This lawsuit centers on a simple accusation: Novo Nordisk knew its blockbuster drug could cause severe gastrointestinal injuries and failed to warn patients or doctors. As of early 2026, more than 10,000 claims have been consolidated in federal court.

In this guide, you’ll find everything you need to know. That includes the latest 2026 case updates, who qualifies, estimated settlement amounts, and exactly how to file. Over $100 billion in Ozempic sales makes this one of the highest-stakes drug lawsuits in U.S. history.

Novo Nordisk Ozempic Lawsuit

The Novo Nordisk Ozempic lawsuit is a mass tort action alleging the pharmaceutical giant failed to adequately warn patients about serious gastrointestinal side effects caused by its semaglutide-based drug. Plaintiffs claim Novo Nordisk prioritized profits over patient safety, hiding evidence that Ozempic could cause life-altering digestive injuries.

The lawsuit targets Novo Nordisk A/S, the Denmark-based company that manufactures and markets Ozempic. Originally approved by the FDA in 2017 for type 2 diabetes management, Ozempic became a cultural phenomenon when doctors began prescribing it off-label for weight loss.

That popularity came at a cost. Thousands of patients developed severe conditions they say were never mentioned in Ozempic’s prescribing information or marketing materials.

The core legal theory is called “failure to warn.” In plain terms, plaintiffs say Novo Nordisk had data showing Ozempic could paralyze the stomach and cause intestinal blockages. Instead of updating labels or alerting the public, the company allegedly stayed quiet while sales soared past $18 billion annually.

Think of it like a car manufacturer knowing the brakes fail at high speed but choosing not to issue a recall. That’s essentially what these lawsuits accuse Novo Nordisk of doing with Ozempic’s safety information.

Ozempic Lawsuit Update 2026

As of 2026, the Ozempic litigation has entered a critical new phase with bellwether trial selections underway and discovery disputes reaching resolution. The case has grown from a few hundred complaints to over 10,000 individual claims consolidated in MDL 3094.

Judge Gene E.K. Pratter has set an aggressive schedule for 2026. Key pretrial motions, including Daubert hearings on expert testimony, are expected in the first half of the year.

Several major developments define the 2026 landscape of this case:

• Bellwether trial pool: Roughly 40 to 50 cases have been selected for the initial trial pool, with the first bellwether trials anticipated for late 2026 or early 2027
• Discovery completion: Both sides have exchanged millions of documents, including internal Novo Nordisk emails and safety reports
• FDA label update: The FDA required Novo Nordisk to add gastroparesis language to Ozempic’s label in 2023, which plaintiffs argue proves the company knew about the risk earlier
• New filings: Hundreds of new cases continue to be filed monthly as more patients connect their injuries to Ozempic use

The pace of this litigation matters. Settlement negotiations often accelerate once bellwether cases are selected because both sides can finally see how real juries might react to the evidence.

Novo Nordisk has denied all wrongdoing. The company maintains that Ozempic’s labeling was adequate and that gastrointestinal side effects were disclosed.

Ozempic Lawsuit Settlement Amounts

No Ozempic settlements have been finalized as of early 2026, but legal analysts project individual payouts ranging from $100,000 to over $1 million depending on case severity. Settlement talks are expected to intensify once bellwether trials produce verdicts.

These projections come from comparing the Ozempic litigation to similar pharmaceutical mass torts. Cases involving permanent gastroparesis or surgical intervention tend to fall at the higher end.

Several factors drive individual settlement values:

• Duration of Ozempic use and the dosage prescribed
• Severity of the injury and whether it required surgery
• Medical documentation connecting the injury to Ozempic
• Lost wages and earning capacity from being unable to work
• Pain and suffering including emotional distress

The total value of the Ozempic litigation could reach billions of dollars given the number of claimants and the severity of injuries reported. For context, the opioid litigation settled for over $26 billion, and legal experts see parallels in scale.

Key Takeaway: The Novo Nordisk Ozempic lawsuit has ballooned to over 10,000 claims, with projected individual settlements ranging from $50,000 to over $1.5 million based on injury severity.

Who Qualifies for Ozempic Lawsuit

You may qualify for the Ozempic lawsuit if you took Ozempic or another semaglutide-based drug and developed serious gastrointestinal side effects. The key requirement is a medical diagnosis linking your condition to the medication.

Eligibility isn’t automatic. You’ll need to meet specific criteria that attorneys and courts use to evaluate whether your case has merit.

Core Eligibility Requirements:

• You were prescribed Ozempic, Wegovy, or Rybelsus
• You developed gastroparesis, stomach paralysis, bowel obstruction, or severe gastrointestinal injury
• A doctor diagnosed your condition during or after taking the medication
• You have medical records documenting both the prescription and the injury
• Your injury required medical treatment (ER visits, hospitalization, surgery, or ongoing care)

Some cases are stronger than others. A patient who spent two weeks in the hospital with a confirmed gastroparesis diagnosis has a much stronger claim than someone who experienced mild nausea.

People who took Ozempic for weight loss (off-label) and people who took it for diabetes both qualify. The lawsuit doesn’t distinguish between prescribed uses.

If you’re unsure whether you qualify, gathering your medical records is the single most important step you can take right now.

Ozempic Gastroparesis Lawsuit

Gastroparesis is the most common injury cited in Ozempic lawsuits. This condition occurs when the stomach muscles stop working properly, causing food to sit in the stomach for hours or even days instead of moving through the digestive system normally.

The medical term literally means “stomach paralysis.” Patients with gastroparesis experience severe nausea, vomiting, bloating, abdominal pain, and dangerous weight loss.

Ozempic works by slowing gastric emptying to help control blood sugar. Plaintiffs argue that Novo Nordisk knew this mechanism could go too far, essentially shutting down stomach function entirely in some patients.

Symptoms of Ozempic-Related Gastroparesis:

• Persistent nausea and vomiting that won’t stop
• Feeling full after eating only a few bites
• Severe abdominal bloating and pain
• Unintended and rapid weight loss
• Acid reflux and heartburn that doesn’t respond to treatment
• Dehydration from inability to keep food or liquids down

Studies published in the Journal of the American Medical Association (JAMA) in 2023 found that GLP-1 users faced a significantly higher risk of gastroparesis compared to non-users. That research became a cornerstone of the litigation.

For many plaintiffs, gastroparesis became a permanent condition. Some now rely on feeding tubes. Others require daily medication just to eat small meals without vomiting.

The connection between Ozempic and gastroparesis is no longer seriously disputed in medical literature. The real legal question is whether Novo Nordisk warned people adequately before they started taking the drug.

Ozempic Side Effects Lawsuit

The Ozempic side effects lawsuit covers a range of serious injuries beyond gastroparesis alone. Plaintiffs have reported bowel obstructions, intestinal blockages, pancreatitis, gallbladder disease, and even suicidal ideation linked to semaglutide use.

Novo Nordisk’s original prescribing label mentioned common side effects like nausea and diarrhea. What it didn’t mention, according to lawsuits, were the severe and potentially permanent conditions that thousands of patients later developed.

The legal argument is straightforward. Drug companies have a legal duty to inform patients and prescribing doctors about known risks. If they fail to do so, and patients get hurt, that’s grounds for a product liability lawsuit.

Internal documents obtained during discovery reportedly show that Novo Nordisk received adverse event reports about these conditions years before updating its labels. That delay is at the heart of the “failure to warn” claims.

What makes this case different from typical drug lawsuits is the sheer volume of patients affected. Ozempic was prescribed to millions of people worldwide, making the potential pool of injured plaintiffs enormous.

Key Takeaway: Ozempic lawsuits cover multiple severe side effects beyond gastroparesis, including bowel obstruction and pancreatitis, and internal documents may show Novo Nordisk knew about these risks earlier than disclosed.

How to File Ozempic Lawsuit

Filing an Ozempic lawsuit starts with contacting a qualified attorney who handles pharmaceutical mass tort cases. Most firms offer free case evaluations and work on a contingency fee basis, meaning you pay nothing upfront.

Here’s the step-by-step process most claimants follow:

Step 1: Gather Your Medical Records
Collect all records showing your Ozempic prescription, dosage, duration of use, and any diagnoses or treatments for gastrointestinal conditions. Hospital records, pharmacy records, and doctor’s notes all matter.

Step 2: Contact an Attorney
Reach out to a law firm experienced in GLP-1 litigation. During the free consultation, they’ll review your medical history and determine if your case qualifies.

Step 3: Case Filing
Your attorney files a complaint in federal court. Most new Ozempic cases are automatically transferred to MDL 3094 in the Eastern District of Pennsylvania.

Step 4: Discovery and Waiting
Once filed, your case joins the broader MDL. Your attorney may request additional medical records, depositions, or expert evaluations.

Step 5: Settlement or Trial
Most mass tort cases settle before trial. Your attorney will advise you if a settlement offer is fair or if going to trial makes more sense for your situation.

You don’t need to live near Philadelphia where the MDL is located. Attorneys file cases remotely from every state.

Ozempic Class Action Lawsuit

The Ozempic litigation is not technically a class action lawsuit. It’s a multidistrict litigation (MDL), which works differently and often benefits plaintiffs more in pharmaceutical cases.

Understanding this distinction matters because it affects how much money you could receive. In a class action, all members share one settlement pot equally. In an MDL, each plaintiff’s case is evaluated individually based on their specific injuries.

Think of it this way. A class action is like splitting a pizza equally among 50 people. An MDL is like each person ordering their own meal based on how hungry they are. If your injury is severe, you could receive significantly more than someone with milder symptoms.

That said, people commonly search for “Ozempic class action” because it’s the term most folks know. What they’re really looking for is the MDL, which is the actual legal vehicle for these claims.

The MDL process consolidates pretrial activities like discovery and expert challenges. But when it comes time for settlement negotiations or trials, each case stands on its own.

Ozempic MDL Status 2026

MDL 3094 is the central hub for all federal Ozempic lawsuits, and as of 2026, it’s entering its most active phase yet. The multidistrict litigation is housed in the U.S. District Court for the Eastern District of Pennsylvania under Judge Gene E.K. Pratter.

Here’s where things stand:

• Total pending cases: Over 10,000 individual complaints as of early 2026
• Discovery status: Substantially complete, with both sides having exchanged millions of pages of internal documents
• Expert witnesses: Daubert challenges (challenges to whether expert testimony is admissible) are being heard in mid-2026
• Bellwether selection: A pool of trial-ready cases has been identified
• Settlement talks: Informal negotiations have begun between plaintiff leadership and Novo Nordisk’s legal team

The MDL structure means that your individual case is managed locally by your attorney while the big-picture legal strategy plays out in Philadelphia. You don’t attend hearings or travel unless your specific case is selected as a bellwether.

Quick Facts: MDL 3094

• Created: August 2023
• Court: Eastern District of Pennsylvania
• Judge: Gene E.K. Pratter
• Defendants: Novo Nordisk A/S, Novo Nordisk Inc.
• Related defendants: Eli Lilly (Mounjaro claims in same MDL)

The speed of MDL 3094 is notable. Compared to other pharmaceutical MDLs, this one is moving relatively fast due to public interest and the volume of filings.

Key Takeaway: MDL 3094 is entering its most active phase in 2026, with discovery wrapping up, expert testimony challenges underway, and bellwether trial selections moving forward.

A related guide: James Henry Lawsuit 2026: Full Settlement and Claim Guide

Ozempic Stomach Paralysis Claims

Stomach paralysis, the clinical term for severe gastroparesis, sits at the center of nearly every Ozempic claim. Patients describe a condition where their stomach simply stops functioning, leading to debilitating symptoms that can last months or become permanent.

The mechanism isn’t mysterious. Ozempic’s active ingredient, semaglutide, works by mimicking a hormone called GLP-1 that slows gastric emptying. In some patients, that slowing effect goes haywire, and the stomach essentially shuts down.

Plaintiffs describe the experience as terrifying. Imagine eating a few bites of food and feeling like your stomach will never empty. Vomiting for hours. Being unable to keep down water. Losing 30, 40, even 50 pounds in a matter of weeks.

Common Progression of Ozempic Stomach Paralysis:

• Patient starts Ozempic at standard dosage
• Mild nausea begins within the first few weeks (often dismissed as normal)
• Nausea worsens; vomiting becomes frequent
• Patient visits ER with severe abdominal pain and dehydration
• Gastric emptying study confirms gastroparesis diagnosis
• Treatment options are limited; some patients need feeding tubes

Medical studies have shown that GLP-1 receptor agonists can reduce gastric motility by 35% to 50% in some patients. That reduction can trigger full stomach paralysis in susceptible individuals.

The strongest claims involve patients who developed stomach paralysis within the first six months of starting Ozempic and who have gastric emptying tests confirming the diagnosis. These diagnostic tests, often called scintigraphy studies, provide objective evidence that courts find highly persuasive.

Ozempic Bellwether Trials 2026

Bellwether trials are test cases selected from the larger MDL to go before a jury. Their outcomes help both sides gauge how future cases might play out and often drive settlement negotiations. The first Ozempic bellwether trials are expected in late 2026 or early 2027.

Here’s how the bellwether process works in MDL 3094:

Selection Phase (2025 to 2026): Both plaintiff and defense attorneys propose cases from the MDL pool. These cases are chosen to represent a cross-section of injuries, geographic locations, and claim types.

Preparation Phase (mid-2026): Selected bellwether cases undergo intensive preparation, including depositions, expert reports, and pretrial motions specific to each case.

Trial Phase (late 2026 to 2027): The first cases go to trial. Jury verdicts establish a value benchmark for the remaining thousands of claims.

Bellwether results are not binding on other cases. But they’re enormously influential. If juries award large verdicts against Novo Nordisk, the company faces massive pressure to settle the remaining cases rather than risk thousands of individual trials.

Conversely, if Novo Nordisk wins bellwether verdicts, plaintiffs’ settlement leverage decreases. That’s why both sides take bellwether selection extremely seriously.

For individual plaintiffs, the bellwether process means patience. Most cases won’t go to trial individually. But the bellwether outcomes will directly influence what settlement offers look like.

Novo Nordisk Lawsuit Payout

Novo Nordisk has not yet paid any settlements in the Ozempic litigation as of early 2026. Payouts are expected to begin after bellwether trial results establish case values, likely in 2027 or 2028.

When payouts do happen, several factors will determine how much each plaintiff receives:

Factors That Increase Payout:

• Permanent injury (lifelong gastroparesis)
• Need for surgical intervention or feeding tube
• Extended hospitalization (multiple weeks)
• Significant lost wages or career impact
• Strong medical documentation linking injury to Ozempic
• Young age at time of injury (longer period of suffering)

Factors That Decrease Payout:

• Pre-existing gastrointestinal conditions
• Short duration of Ozempic use
• Symptoms that resolved after stopping the drug
• Limited medical records or gaps in treatment
• Weak causal connection between Ozempic and injury

How does Novo Nordisk’s financial position affect payouts? The company reported $35.4 billion in revenue for 2024, with Ozempic alone generating over $18 billion. Novo Nordisk has the financial capacity to fund a massive settlement.

In pharmaceutical litigation, defendants with deep pockets and blockbuster drugs tend to settle for larger amounts because juries are unsympathetic to companies that profited enormously from a product that hurt people.

Key Takeaway: Ozempic payouts haven’t started yet, but Novo Nordisk’s massive revenue from the drug means the company has the financial capacity to fund a substantial settlement once bellwether trials set the baseline.

Ozempic Lawsuit Eligibility Requirements

Meeting the eligibility requirements for the Ozempic lawsuit comes down to four basic elements: you took the drug, you got hurt, you have records to prove both, and the timing makes sense. Let’s break each one down.

Requirement 1: Verified Ozempic Use
You must show that you were prescribed Ozempic, Wegovy, or Rybelsus. Pharmacy records, prescription bottles, insurance claims, or medical charts all serve as proof. Off-label use (like taking Ozempic for weight loss instead of diabetes) still qualifies.

Requirement 2: Qualifying Injury
Your injury must be one of the conditions listed in the litigation:

• Gastroparesis (stomach paralysis)
• Bowel obstruction or intestinal blockage
• Pancreatitis
• Gallbladder disease or gallbladder removal
• Ileus (intestinal paralysis)
• Severe vomiting requiring hospitalization

Requirement 3: Medical Documentation
You need medical records showing a diagnosis. Self-reported symptoms without a doctor’s confirmation are generally not sufficient to pursue a case.

Requirement 4: Causal Timeline
Your injury must have developed during or shortly after taking the medication. Cases where symptoms appeared years after discontinuing Ozempic face a harder burden of proof.

If you’re missing some records, don’t panic. Attorneys can often obtain medical and pharmacy records on your behalf through legal requests.

Ozempic Bowel Obstruction Lawsuit

Bowel obstruction is the second most common injury in Ozempic lawsuits after gastroparesis. A bowel obstruction occurs when the intestines become partially or completely blocked, preventing food, fluid, and gas from passing through normally.

This condition is a medical emergency. Without treatment, a bowel obstruction can cause the intestine to rupture, leading to infection, sepsis, and potentially death.

Ozempic’s mechanism of slowing gastric emptying doesn’t just affect the stomach. The GLP-1 receptor is present throughout the digestive tract. Plaintiffs argue that semaglutide can slow intestinal motility to dangerous levels, causing material to back up and create blockages.

Warning Signs of Ozempic-Related Bowel Obstruction:

• Severe cramping and abdominal pain
• Inability to pass gas or have bowel movements
• Abdominal swelling and distension
• Vomiting (may include fecal matter in severe cases)
• High fever and rapid heart rate

Many bowel obstruction cases require emergency surgery. Surgeons may need to remove sections of dead or damaged intestine, which creates permanent digestive changes.

Court filings in MDL 3094 include dozens of cases where patients underwent emergency bowel obstruction surgery within months of starting Ozempic. These surgical cases tend to have the highest potential settlement values because the injuries are severe, well-documented, and clearly connected to the medication.

The FDA’s adverse event reporting system (FAERS) shows a notable increase in bowel obstruction reports associated with semaglutide products beginning around 2021, which aligns with Ozempic’s surge in prescriptions.

GLP-1 Drug Lawsuit Novo Nordisk

The GLP-1 drug lawsuit against Novo Nordisk extends beyond Ozempic alone. The litigation encompasses all semaglutide-based products manufactured by the company, including Wegovy (approved for weight management) and Rybelsus (the oral semaglutide tablet).

All three drugs share the same active ingredient: semaglutide. Because the alleged harm stems from semaglutide itself, patients who took any of these products may have valid claims.

The inclusion of Eli Lilly’s Mounjaro and Zepbound in the same MDL is significant. It means the litigation is really about the entire GLP-1 drug class, not just one product.

For Novo Nordisk specifically, the legal exposure is enormous. The company sold semaglutide under three brand names to millions of patients worldwide. If the court finds that semaglutide itself causes these injuries, every product containing it becomes a liability.

GLP-1 drugs work by mimicking a natural hormone that regulates insulin and appetite. They were revolutionary for diabetes and weight loss. But the lawsuits argue that the manufacturers rushed these drugs to market, knowing the gastrointestinal risks but choosing profit over transparent patient safety.

A related guide: Immuno 150 Lawsuit 2026: Updates, Payout and Who Qualifies

Key Takeaway: The lawsuit covers all semaglutide-based drugs from Novo Nordisk, including Ozempic, Wegovy, and Rybelsus, and even extends to Eli Lilly’s GLP-1 products within the same MDL.

Ozempic Lawsuit Deadline to File

There is no single universal deadline to file an Ozempic lawsuit. Deadlines vary by state because each state has its own statute of limitations for personal injury and product liability claims. Most states allow two to three years from the date of injury or discovery of injury.

This is critical. Miss your state’s deadline and you lose the right to file, no matter how strong your case is.

For a deeper understanding, check Live Olympics Lawsuit 2026: Settlement and Filing Update

The “discovery rule” matters here. In many states, the clock doesn’t start ticking until you knew (or should have known) that your injury was caused by Ozempic. So if you were diagnosed with gastroparesis in 2023 but didn’t connect it to Ozempic until 2025, your deadline may extend accordingly.

Don’t wait for the MDL to settle before filing. The MDL process doesn’t pause or extend state filing deadlines. You need to file your individual claim before your state’s deadline expires, even if the MDL won’t reach your case for years.

For anyone reading this in 2026, the clock is running. If your Ozempic-related injury occurred in 2024 and you live in a state with a two-year statute of limitations, your filing deadline could be as soon as 2026. Contact an attorney immediately to confirm your specific deadline.

Ozempic Injury Compensation Amounts

Ozempic injury compensation covers several categories of damages, and understanding these categories helps you estimate what your case might be worth. Compensation isn’t just about medical bills. It includes lost income, pain, suffering, and the long-term impact on your life.

Economic Damages (Calculable Losses):

• Past and future medical expenses
• Hospital stays and emergency room costs
• Prescription costs and ongoing treatment
• Lost wages and reduced earning capacity
• Cost of home care or dietary needs
• Medical equipment (feeding tubes, pumps)

Non-Economic Damages (Quality of Life):

• Physical pain and suffering
• Emotional distress and mental anguish
• Loss of enjoyment of life
• Relationship strain and loss of consortium
• Permanent disability or disfigurement

In mass tort cases like this, attorneys often calculate case value using a multiplier method. They add up your economic damages and multiply by a factor (usually 1.5 to 5) depending on injury severity to account for non-economic losses.

Someone with $100,000 in medical bills and a permanent gastroparesis diagnosis might see their total case value calculated at $300,000 to $500,000 using this method.

Keep every receipt, every medical bill, every record of missed work. Documentation is what turns a good case into a great one.

Novo Nordisk Hiding Side Effects

The allegation that Novo Nordisk deliberately hid Ozempic’s side effects is the backbone of the entire litigation. Plaintiffs argue the company had internal data showing the risk of severe gastrointestinal injuries but chose not to disclose it to patients, doctors, or the FDA in a timely manner.

Here’s the timeline that plaintiffs point to:

• 2017: Ozempic receives FDA approval. The label mentions nausea and diarrhea as common side effects. No mention of gastroparesis.
• 2018 to 2020: Adverse event reports begin accumulating in Novo Nordisk’s pharmacovigilance database and in the FDA’s FAERS system.
• 2021 to 2022: Independent researchers begin publishing data linking GLP-1 drugs to gastroparesis. Novo Nordisk’s label remains unchanged.
• September 2023: Under pressure, the FDA requires Novo Nordisk to add “ileus” (intestinal blockage) to Ozempic’s warning label.
• 2024: Additional label updates include gastroparesis-related language. Plaintiffs argue this came years too late.

The gap between 2018 (when adverse reports began rising) and 2023 (when labels finally changed) is the core of the concealment allegation. Five years of silence while millions of new patients started taking the drug.

Internal company documents obtained during discovery are reportedly damaging. While specific documents remain under protective order, plaintiff attorneys have described emails and reports showing that Novo Nordisk’s safety team flagged gastrointestinal concerns internally but that marketing and executive leadership did not act on those warnings.

Drug companies have a legal obligation called a “duty of ongoing vigilance.” Even after a drug is approved, they must monitor safety data and update warnings when new risks emerge. Plaintiffs say Novo Nordisk violated this duty repeatedly.

This concealment pattern is familiar to anyone who followed the opioid litigation. Companies that knew their products were dangerous and stayed quiet tend to face the harshest penalties, both from juries and in settlement negotiations.

Key Takeaway: Plaintiffs allege Novo Nordisk had internal evidence of Ozempic’s severe side effects for five years before updating the drug’s warning label, and discovery documents reportedly support the concealment claim.

Frequently Asked Questions

How much money can I get from the Ozempic lawsuit?

Most estimates place individual settlements between $50,000 and $1.5 million depending on the severity of your injury.

Cases involving permanent gastroparesis, surgery, or feeding tubes fall at the higher end.

Payouts are expected to begin in 2027 or 2028 after bellwether trials produce results.

What is the deadline to file an Ozempic lawsuit in 2026?

The deadline depends on your state’s statute of limitations, which ranges from two to three years from the date of injury or discovery.

If your injury occurred in 2024, your deadline could arrive as soon as 2026 in states with a two-year window.

Contact an attorney now to confirm your specific deadline before it expires.

Does the Ozempic lawsuit cover people who took Wegovy?

Yes, the lawsuit covers Wegovy, Rybelsus, and Ozempic because all three contain the same active ingredient, semaglutide.

Claims against all Novo Nordisk semaglutide products are consolidated in MDL 3094.

If you took any semaglutide-based drug and were injured, you may qualify.

How long will the Ozempic lawsuit take to settle?

The earliest settlements are expected in 2027 to 2028, following bellwether trial outcomes.

Mass tort pharmaceutical cases of this size typically take three to five years from MDL creation to resolution.

MDL 3094 was created in 2023, placing the estimated settlement window between 2026 and 2028.

Do I need a lawyer to file an Ozempic claim?

You technically can file alone, but it’s strongly recommended to work with an attorney experienced in pharmaceutical mass torts.

Most Ozempic attorneys work on contingency, meaning you pay nothing unless you receive a settlement or verdict.

An attorney handles all filings, medical record requests, and negotiations on your behalf.

This lawsuit against Novo Nordisk represents one of the most significant pharmaceutical cases of the decade. Billions of dollars are at stake, and the window to file your claim is narrowing in many states.

If you took Ozempic, Wegovy, or Rybelsus and experienced serious digestive injuries, gather your medical records now. Check your state’s filing deadline.

The cases are moving fast in 2026. Don’t let the clock run out on your right to compensation.

Don't miss this — Gaming Lawsuit 2026: Who Qualifies and How to File

Worth reading: Lawsuit Attorneys in 2026: Your Guide to Hiring Right

Along the same lines: Finance Lawsuit April 2026: Settlement and Payout Updates

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.